HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Supplemental Data All Versions of this Article: jnumed.109.066993v1 50/12/2033    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Santoro, L. Articles by Pouget, J.-P. Search for Related Content PubMed PubMed Citation Articles by Santoro, L. Articles by Pouget, J.-P.

Noninternalizing Monoclonal Antibodies Are Suitable Candidates for ¹²⁵I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis

¹ Institut de Recherche en Cancérologie de Montpellier, Montpellier, France; ² INSERM, U896, Montpellier, France; ³ Université Montpellier 1, Montpellier, France; ⁴ CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France; ⁵ Service de Médecine Nucléaire, CHU de Nîmes, Nîmes, France; and ⁶ Direction de la Radioprotection de l'Homme, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, France

Correspondence: For correspondence or reprints contact: Jean-Pierre Pouget, Institut de Recherche en Cancérologie de Montpellier, CRLC Val d'Aurelle, 34298 Montpellier Cedex 5, France. E-mail: jean-pierre.pouget{at}valdorel.fnclcc.fr

We have previously shown that, in vitro, monoclonal antibodies (mAbs) labeled with the Auger electron emitter ¹²⁵I are more cytotoxic if they remain at the cell surface and do not internalize in the cytoplasm. Here, we assessed the in vivo biologic efficiency of internalizing and noninternalizing ¹²⁵I-labeled mAbs for the treatment of small solid tumors. Methods: Swiss nude mice bearing intraperitoneal tumor cell xenografts were injected with 37 MBq (370 MBq/mg) of internalizing (anti-HER1) ¹²⁵I-m225 or noninternalizing (anti-CEA) ¹²⁵I-35A7 mAbs at days 4 and 7 after tumor cell grafting. Nonspecific toxicity was assessed using the irrelevant ¹²⁵I-PX mAb, and untreated controls were injected with NaCl. Tumor growth was followed by bioluminescence imaging. Mice were sacrificed when the bioluminescence signal reached 4.5 x 10⁷ photons/s. Biodistribution analysis was performed to determine the activity contained in healthy organs and tumor nodules, and total cumulative decays were calculated. These values were used to calculate the irradiation dose by the MIRD formalism. Results: Median survival (MS) was 19 d in the NaCl-treated group. Similar values were obtained in mice treated with unlabeled PX (MS, 24 d) and 35A7 (MS, 24 d) or with ¹²⁵I-PX mAbs (MS, 17 d). Conversely, mice treated with unlabeled or labeled internalizing m225 mAb (MS, 76 and 77 d, respectively) and mice injected with ¹²⁵I-35A7 mAb (MS, 59 d) showed a significant increase in survival. Irradiation doses were comparable in all healthy organs, independently from the mAb used, whereas in tumors the irradiation dose was 7.4-fold higher with ¹²⁵I-labeled noninternalizing than with internalizing mAbs. This discrepancy might be due to iodotyrosine moiety release occurring during the catabolism of internalizing mAbs associated with high turnover rate. Conclusion: This study indicates that ¹²⁵I-labeled noninternalizing mAbs could be suitable for radioimmunotherapy of small solid tumors and that the use of internalizing mAbs should not be considered as a requirement for the success of treatments with ¹²⁵I Auger electrons.

Key Words: radioimmunotherapy • Auger electrons • solid tumors

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]